ANI Pharmaceuticals (NASDAQ:ANIP) Given Hold Rating at Truist Financial

Truist Financial reissued their hold rating on shares of ANI Pharmaceuticals (NASDAQ:ANIP) in a research note published on Wednesday, MarketBeat reports. They currently have a $60.00 price target on the specialty pharmaceutical company’s stock, down from their prior price target of $80.00.

Several other brokerages also recently weighed in on ANIP. StockNews.com downgraded shares of ANI Pharmaceuticals from a buy rating to a hold rating in a research note on Saturday, September 7th. HC Wainwright restated a buy rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, ANI Pharmaceuticals currently has a consensus rating of Moderate Buy and an average price target of $77.75.

ANI Pharmaceuticals Stock Performance

ANI Pharmaceuticals stock opened at $58.51 on Wednesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.07 and a current ratio of 3.97. The company has a market capitalization of $1.23 billion, a PE ratio of 36.57 and a beta of 0.71. The company has a 50 day moving average price of $61.39 and a 200-day moving average price of $63.88. ANI Pharmaceuticals has a fifty-two week low of $48.20 and a fifty-two week high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 EPS for the quarter, beating the consensus estimate of $0.95 by $0.07. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The business had revenue of $138.00 million during the quarter, compared to analyst estimates of $129.09 million. During the same quarter in the previous year, the business posted $1.06 EPS. The company’s quarterly revenue was up 18.5% compared to the same quarter last year. As a group, equities analysts forecast that ANI Pharmaceuticals will post 3.5 earnings per share for the current year.

Insider Transactions at ANI Pharmaceuticals

In related news, COO Muthusamy Shanmugam sold 11,000 shares of ANI Pharmaceuticals stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $63.38, for a total value of $697,180.00. Following the completion of the transaction, the chief operating officer now owns 671,620 shares in the company, valued at approximately $42,567,275.60. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, COO Muthusamy Shanmugam sold 11,000 shares of ANI Pharmaceuticals stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $63.38, for a total value of $697,180.00. Following the sale, the chief operating officer now owns 671,620 shares in the company, valued at $42,567,275.60. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Chad Gassert sold 20,000 shares of the company’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $63.44, for a total transaction of $1,268,800.00. Following the transaction, the senior vice president now owns 193,226 shares of the company’s stock, valued at approximately $12,258,257.44. The disclosure for this sale can be found here. Insiders have sold 65,757 shares of company stock valued at $4,075,585 in the last 90 days. 12.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of ANIP. Innealta Capital LLC acquired a new position in shares of ANI Pharmaceuticals during the 2nd quarter worth approximately $65,000. Ridgewood Investments LLC purchased a new position in ANI Pharmaceuticals during the second quarter worth about $85,000. SG Americas Securities LLC purchased a new stake in shares of ANI Pharmaceuticals in the 1st quarter valued at approximately $106,000. ADAR1 Capital Management LLC purchased a new stake in shares of ANI Pharmaceuticals during the 4th quarter valued at approximately $132,000. Finally, Clear Street Markets LLC acquired a new position in ANI Pharmaceuticals in the fourth quarter valued at approximately $140,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.